Cargando…

PB2028: TREATING MULTIPLE MYELOMA IN A RESOURCE-LIMITED SETTING: REAL-WORLD OUTCOMES

Detalles Bibliográficos
Autores principales:	Martinez, G., Seguro, F., Jacomassi, M., Visnadi, H., Atanazio, M., Szor, R., Neffá, P., Pereira, T., Silva, W., Dorlhiac-Llacer, P., Velasques, R., Bassolli, L., Rocha, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431401/ http://dx.doi.org/10.1097/01.HS9.0000850944.84571.7f

Ejemplares similares

PB2028: ACQUIRED Α-THALASSEMIA IN A PATIENT WITH HIGH-RISK MYELODYSPLASTIC SYNDROME AND BONE MARROW FIBROSIS: CASE REPORT AND LITERATURE REVIEW
por: Chissan, Sofia, et al.
Publicado: (2023)

PB2015: YOUNG ADULTS WITH MULTIPLE MYELOMA – A SINGLE CENTER EXPERIENCE
por: Dos Santos Marques, I., et al.
Publicado: (2022)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.
por: Fonseca, R., et al.
Publicado: (2022)

PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA
por: Vlachová, M., et al.
Publicado: (2022)

PB2037: RESULTS FROM PIMMS, A UK MYELOMA RESEARCH ALLIANCE (UKMRA) STUDY OF OUTCOMES AND TOXICITY OF PANOBINOSTAT WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MYELOMA IN A REAL WORLD SETTING
por: Waters, J., et al.
Publicado: (2022)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
por: Harsløf, Mads, et al.
Publicado: (2023)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
por: Crusoe, E., et al.
Publicado: (2022)

LHCb Upgrade(s) - up to 2028
por: Jacobsson, R
Publicado: (2013)

PB1990: MULTIPLE MYELOMA IN THE ELDERLY: A MONOCENTRIC EXPERIENCE
por: Charfi, H., et al.
Publicado: (2022)

PB2278: INVESTIGATION ON THE STATUS OF INFECTION IN PATIENTS WITH MULTIPLE MYELOMA
por: Lan, D., et al.
Publicado: (2022)

PB1975: THE RESEARCH ON THE MECHANISM OF RRAD GENE IN MULTIPLE MYELOMA
por: Yi, C., et al.
Publicado: (2022)

PB1981: EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA
por: Bougherira, S., et al.
Publicado: (2022)

PB1969: FUNCTIONAL CHARACTERIZATION OF SUSCEPTIBILITY LOCI TO MULTIPLE MYELOMA
por: Shokouhi, M., et al.
Publicado: (2022)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Krishnan, A., et al.
Publicado: (2022)

Consolidative mediastinal radiotherapy for advanced-stage classical Hodgkin lymphoma with bulky disease in patients who achieve complete response after chemotherapy in PET-CT era
por: Atanazio, Marcelo Junqueira, et al.
Publicado: (2022)

PB2186: INTENSITY OF THE CONDITIONING REGIMEN AND TIMING OF AUTOGRAFT ENGRAFTMENT IN PATIENTS WITH MULTIPLE MYELOMA
por: Kostroma, I., et al.
Publicado: (2022)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE
por: Hultcrantz, Malin, et al.
Publicado: (2023)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
por: Semenova, N. Y., et al.
Publicado: (2022)

PB2086: SIMULTANEOUS DIAGNOSIS OF MULTIPLE MYELOMA AND MYELODYSPLASIA: CASE REPORT.
por: Benabed, Khaled, et al.
Publicado: (2023)

PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS
por: Gkioka, Annita-Ioanna, et al.
Publicado: (2023)

PB2156: CLINICAL AND PROGNOSTIC FACTORS IN MULTIPLE MYELOMA IN THE GOMEL REGION
por: Kozich, Zhanna, et al.
Publicado: (2023)

PB2157: AUTOSCT IN PATIENTS WITH MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT NEPHROPATHY
por: Karimova, Ekaterina, et al.
Publicado: (2023)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

PB1955: THE AGENDA FOR FUTURE MULTIPLE MYELOMA RESEARCH ACCORDING TO PATIENTS, CAREGIVERS, AND CLINICIANS
por: Fowler, S., et al.
Publicado: (2022)

PB1971: FREQUENCY AND CHARACTERISTICS OF DEL(6Q) IN PATIENTS WITH MULTIPLE MYELOMA FROM LATIN-AMERICAN COUNTRIES. A REAL-WORLD STUDY
por: Stella, F., et al.
Publicado: (2022)

PB2027: PROGNOSTICATION IN THE EVERYDAY MYELOMA CLINIC. A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS VALIDATED IN REAL WORLD POPULATIONS
por: Redder, L., et al.
Publicado: (2022)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA
por: Nameera, Rahmathullah Sulaimankutty, et al.
Publicado: (2023)

PB2036: RISK AND PATTERN OF INFECTIONS IN NEWLY DIAGNOSED PATIENTS OF MULTIPLE MYELOMA VACCINATED UPFRONT AGAINST PNEUMOCOCCUS & INFLUENZA
por: VA, A., et al.
Publicado: (2022)

PB2010: RETROSPECTIVE STUDY OF RELAPSED/REFRACTORY MYELOMA PATIENTS FROM AN INDIAN TERTIARY CENTRE: RESPONSE MATTERS!!
por: Lavu, R. R., et al.
Publicado: (2022)

PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION
por: Sridhar, Amrutha, et al.
Publicado: (2023)

PB2073: EVALUATION OF THE PLASMA METABOLOMIC PROFILE OF MGUS AND MULTIPLE MYELOMA PATIENTS
por: Ciesluk, Klaudia, et al.
Publicado: (2023)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
por: Zhong, Yuping, et al.
Publicado: (2023)

PB2126: RETROSPECTIVE REAL LIFE STUDY OF MULTIPLE MYELOMA STATUS AT DEATH.
por: Pérez, Mónica Fernández, et al.
Publicado: (2023)

PB2145: IMPACT OF A SIZE OF BONE PLASMACYTOMA ON THE COURSE OF MULTIPLE MYELOMA
por: Mamaeva, Elizaveta, et al.
Publicado: (2023)

PB1996: TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS
por: Duane, C., et al.
Publicado: (2022)

PB1968: EPIGENETIC AND GENETIC INVESTIGATION OF SOCS-1 GENE IN PATIENTS WITH MULTIPLE MYELOMA
por: Serin, I., et al.
Publicado: (2022)

PB2029: MULTIPLE MYELOMA AND SPINAL CORD COMPRESSION: THE EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Kallel, F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v8lfrej36rcf88k71cqdn9aolh